Ongoing and active de-escalation studies for early-stage HER2-positive breast cancer were identified by searching ClinicalTrials.gov on 11 March 2022 and using the terms “HER2-positive breast cancer” and “de-escalation” (Table 1) [48]. The gene discussed is ERBB2; the disease is breast cancer.